Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

TOI


Top 10 Correlated ETFs

TOI


Top 10 Correlated Stocks

TOI


In the News

09:05 29 Nov 2022 TOI

Topicus.com's Q3 Earnings Digest: Context Is Important

Topicus recently reported Q3 earnings. They were very good at first sight. Margins compressed, but this is not uncommon for a serial acquirer such as Topicus. We explain why.

07:53 29 Nov 2022 TOI

The Oncology Institute, Inc. (TOI) Q3 2022 Earnings Call Transcript

The Oncology Institute, Inc. (NASDAQ:TOI ) Q3 2022 Earnings Conference Call November 9, 2022 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Brad Hively - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Brian Tanquilut - Jefferies Sandy Draper - Guggenheim Operator Good afternoon, and welcome to The Oncology Institute's Third Quarter 2022 Earnings Conference Call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A.

07:14 29 Nov 2022 TOI

Topicus.com: Just Buy Constellation Software Instead

Topicus.com Inc. has a strong history of creating shareholder value, and is owned by one of the greatest serial acquirers in financial market history. The inflation driven market turmoil of 2022 has hit software companies the hardest, providing companies with experienced management teams and cash opportunities to salvage through the wreckages that remain.

04:40 29 Nov 2022 TOI

The Oncology Institute, Inc. (TOI) CEO Brad Hively on Q2 2022 Results - Earnings Call Transcript

The Oncology Institute, Inc. (NASDAQ:TOI ) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Brad Hively - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Taji Phillips - Jefferies Christian Borgmeyer - Cowen Operator Good afternoon, and welcome to The Oncology Institute's Second Quarter 2022 Earnings Conference Call. Today's call is being recorded and we have allocated one hour for prepare marks and Q&A.

03:57 29 Nov 2022 TOI

Topicus.com Update: Calculated Expansion

Topicus.com made a record number in both amount and number of acquisitions during 2022. New geographies have been reached, expanding the acquisition network even further.

11:10 29 Nov 2022 TOI

The Oncology Institute, Inc's (TOI) CEO Brad Hively on Q1 2022 Results - Earnings Call Transcript

The Oncology Institute, Inc. (NASDAQ:TOI ) Q1 2022 Earnings Conference Call May 11, 2022 5:00 PM ET Company Participants Mihir Shah – Chief Financial Officer Brad Hively – Chief Executive Officer Conference Call Participants Brian Tanquilut – Jefferies Gary Taylor – Cowen Operator Good afternoon and welcome to The Oncology Institute's First Quarter 2022 Earnings Conference Call. Today's call is being recorded and we have allocated one hour for prepare marks and Q&A.

08:57 29 Nov 2022 TOI

The Oncology Institute, Inc. (TOI) CEO Brad Hively on Q4 2021 Results - Earnings Call Transcript

The Oncology Institute, Inc. (TOI) CEO Brad Hively on Q4 2021 Results - Earnings Call Transcript

03:00 29 Nov 2022 TOI

The Oncology Institute: Capitalizing On Clinical Research Contracts

The Oncology Institute manages community-based oncology practices numbering 55 across four states in the U.S.

Financial details

Company Rating
Buy
Market Cap
109.96M
Income
1.1M
Revenue
384.06M
Book val./share
1.77
Cash/share
1.25
Dividend
-
Dividend %
-
Employees
658
Optionable
No
Shortable
Yes
Earnings
09 Nov 2022
P/E
50.67
Forward P/E
-
PEG
-5.36
P/S
0.29
P/B
0.86
P/C
1.13
P/FCF
-1.28
Quick Ratio
3.83
Current Ratio
4.37
Debt / Equity
0.79
LT Debt / Equity
0.79
-
-
EPS (TTM)
-0.03
EPS next Y
-
EPS next Q
-
EPS this Y
-67.88%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
6.66%
EPS Q/Q
-38.33%
-
-
-
-
SMA20
-65.72%
SMA50
-67.62%
SMA100
-69.38%
Inst Own
32.01%
Inst Trans
3.28%
ROA
-
ROE
1%
ROC
-0.39%
Gross Margin
55%
Oper. Margin
-26%
Profit Margin
-
Payout
-
Shs Outstand
73.5M
Shs Float
26.85M
-
-
-
-
Target Price
8
52W Range
1.445-12.66
52W High
-88.25%
52W Low
+41%
RSI
11.41
Rel Volume
1.17
Avg Volume
172.34K
Volume
202.34K
Perf Week
-28.79%
Perf Month
-68.24%
Perf Quarter
-78.99%
Perf Half Y
-84.35%
-
-
-
-
Beta
1.7137
-
-
Volatility
0.15%, 1.36%
Prev Close
-7.24%
Price
1.41
Change
-7.24%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2020-12-31 2021-12-31
Revenue per share
6.523.07
Net income per share
-0.5-0.16
Operating cash flow per share
0.02-0.49
Free cash flow per share
-0.02-0.54
Cash per share
0.211.73
Book value per share
0.981.57
Tangible book value per share
-0.20.9
Share holders equity per share
0.981.57
Interest debt per share
0.430.01
Market cap
310.79M396.72M
Enterprise value
316.72M282.61M
P/E ratio
-21.7-36.31
Price to sales ratio
1.661.95
POCF ratio
611.5-12.14
PFCF ratio
-453.12-11.1
P/B Ratio
11.063.81
PTB ratio
11.063.81
EV to sales
1.691.39
Enterprise value over EBITDA
-28.05-35.61
EV to operating cash flow
623.17-8.65
EV to free cash flow
-461.77-7.91
Earnings yield
-0.05-0.03
Free cash flow yield
0-0.09
Debt to equity
0.230
Debt to assets
0.570.49
Net debt to EBITDA
-0.5314.38
Current ratio
1.045.17
Interest coverage
-23.62-143.31
Income quality
-0.042.99
Dividend Yield
00
Payout ratio
00
Sales general and administrative to revenue
00
Research and developement to revenue
00
Intangibles to total assets
0.510.22
Capex to operating cash flow
-2.350.09
Capex to revenue
-0.01-0.02
Capex to depreciation
-0.38-0.91
Stock based compensation to revenue
00.12
Graham number
3.312.42
ROIC
-0.22-0.26
Return on tangible assets
-0.45-0.07
Graham Net
-0.570.52
Working capital
1.11M124.26M
Tangible asset value
-5.64M59.29M
Net current asset value
-7.87M54.78M
Invested capital
0.420
Average receivables
17.26M19.25M
Average payables
12.64M14.1M
Average inventory
4.35M5.4M
Days sales outstanding
33.5938.2
Days payables outstanding
30.6335.02
Days of inventory on hand
10.5514.49
Receivables turnover
10.879.56
Payables turnover
11.9110.42
Inventory turnover
34.625.19
ROE
-0.51-0.1
Capex per share
-0.04-0.05

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
02.90.750.830.9
Net income per share
-0.02-0.140.26-0.07-0.04
Operating cash flow per share
0.2-0.45-0.23-0.14-0.28
Free cash flow per share
0.24-0.5-0.25-0.16-0.3
Cash per share
0.051.631.290.881.25
Book value per share
-1.831.491.81.71.77
Tangible book value per share
-0.920.851.20.961.08
Share holders equity per share
-1.831.491.81.71.77
Interest debt per share
0.1700.260.261.49
Market cap
285.78M682.01M522.29M369.36M334.21M
Enterprise value
289.13M567.89M446.32M324.26M378.85M
P/E ratio
-165.37-16.956.77-16.93-31.25
Price to sales ratio
03.369.476.065.14
POCF ratio
50.55-21.54-30.76-35.59-16.38
PFCF ratio
41.54-19.65-29.04-31.51-15.48
P/B Ratio
-5.436.553.962.982.61
PTB ratio
-5.436.553.962.982.61
EV to sales
02.88.095.325.83
Enterprise value over EBITDA
-106.54-58.2421.74-74.96-19.94K
EV to operating cash flow
51.14-17.93-26.28-31.24-18.57
EV to free cash flow
42.03-16.36-24.82-27.66-17.55
Earnings yield
0-0.010.04-0.01-0.01
Free cash flow yield
0.02-0.05-0.03-0.03-0.06
Debt to equity
000.110.120.79
Debt to assets
1.830.490.360.350.55
Net debt to EBITDA
-1.2411.7-3.710.43-2.35K
Current ratio
0.545.174.443.114.37
Interest coverage
-271.79-690.15-249.61-300.07-13.42
Income quality
-13.093.15-0.881.97.63
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.020.220.210.280.18
Capex to operating cash flow
00.030.060.130.06
Capex to revenue
00-0.02-0.02-0.02
Capex to depreciation
0-0.95-1.02-1.22-1.05
Stock based compensation to revenue
00.120.160.110.1
Graham number
0.792.23.271.691.22
ROIC
0.06-0.24-0.11-0.12-0.08
Return on tangible assets
-0.01-0.060.12-0.04-0.01
Graham Net
-1.250.490.590.34-0.47
Working capital
-25.83M124.26M108.32M76.08M110.78M
Tangible asset value
-26.42M59.29M87.8M70.12M78.25M
Net current asset value
-26.73M54.78M65.33M46.45M-12.24M
Invested capital
-0.0900.140.150.83
Average receivables
25.81M25.31M27.58M29.37M32.37M
Average payables
15.8M14.73M13.25M13.9M12.53M
Average inventory
7.17M7.51M8.18M8.58M9.3M
Days sales outstanding
09.4242.0843.3949
Days payables outstanding
031.8526.4625.1327.79
Days of inventory on hand
013.1816.3215.5124.96
Receivables turnover
09.562.142.071.84
Payables turnover
02.833.43.583.24
Inventory turnover
06.835.515.83.61
ROE
0.01-0.10.15-0.04-0.02
Capex per share
0-0.01-0.01-0.02-0.02

Frequently Asked Questions

What is The Oncology Institute, Inc. stock symbol ?

The Oncology Institute, Inc. is a US stock , located in Cerritos of Ca and trading under the symbol TOI

Is The Oncology Institute, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $8. The lowest prediction is $6 and the highest is $10

What is TOI stock prediction ?

With a median analyst target price of $6, 1 stock analysts have made 1 forecasts in last 90 days. $6 is the lowest and $6 is the greatest projection.

What is The Oncology Institute, Inc. stock quote today ?

The Oncology Institute, Inc. stock price is $1.41 today.

Is The Oncology Institute, Inc. stock public?

Yes, The Oncology Institute, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap